Compare ESE & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESE | PTCT |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.3B |
| IPO Year | N/A | 2013 |
| Metric | ESE | PTCT |
|---|---|---|
| Price | $199.88 | $79.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 17 |
| Target Price | ★ $237.50 | $73.76 |
| AVG Volume (30 Days) | 267.4K | ★ 2.3M |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ 193.06 | N/A |
| EPS | ★ 11.55 | 8.94 |
| Revenue | $1,095,388,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $18.95 | $128.32 |
| Revenue Next Year | $6.83 | N/A |
| P/E Ratio | $44.27 | ★ $8.79 |
| Revenue Growth | 19.18 | ★ 97.54 |
| 52 Week Low | $127.17 | $35.95 |
| 52 Week High | $229.46 | $87.50 |
| Indicator | ESE | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 60.29 |
| Support Level | $196.24 | $73.78 |
| Resistance Level | $208.89 | $76.17 |
| Average True Range (ATR) | 5.26 | 2.69 |
| MACD | -0.12 | -0.21 |
| Stochastic Oscillator | 38.93 | 90.86 |
ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace and Defense, Utility Solutions Group (USG), and Test. The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.